Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05121948 |
Title | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) |
Recruitment | Terminated |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | HiberCell, Inc. |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
UC San Diego Moores Cancer Center | La Jolla | California | 92093 | United States | Details | |
University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | United States | Details | |
Washington University School of Medicine | Saint Louis | Missouri | 63110 | United States | Details | |
Sarah Cannon Research Institute /Tennessee Oncology | Nashville | Tennessee | 37203 | United States | Details | |
Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States | Details | |
The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
Swedish Cancer Institute | Seattle | Washington | 98104 | United States | Details |